Report on the 4th European Breast Cancer Conference, Hamburg, Germany, 16-20 March 2004.
The 4th European Breast Cancer Conference, organized under the auspices of the European Organization for Research and Treatment of Cancer Breast Cancer Group, of the European Breast Cancer Coalition (Europa Donna) and of the European Society of Mastology (EUSOMA), was held in Hamburg, Germany on 16-20 March 2004. The leading theme of the conference was partnership among scientists, clinicians, carers, advocates and patients. The present article provides a brief description of the most important conference presentations on molecular biology, epidemiology, prevention, pathology, diagnosis and treatment at all stages of breast cancer.
Senkus-Konefka
Elzbieta
E
Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland. elsenkus@amg.gda.pl
Jassem
Jacek
J
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D047072:Aromatase Inhibitors; D001711:Biotransformation / Q000235:genetics / Q000502:physiology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000401:mortality; D017024:Chemotherapy, Adjuvant / Q000639:trends; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data / Q000639:trends; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D064420:Drug-Related Side Effects and Adverse Reactions; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D020869:Gene Expression Profiling / Q000639:trends; D016158:Genes, p53 / Q000502:physiology; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000517:prevention & control; D017239:Paclitaxel / Q000627:therapeutic use; D010597:Pharmacogenetics / Q000639:trends; D013629:Tamoxifen / Q000008:administration & dosage / Q000627:therapeutic use; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D047072:Aromatase Inhibitors; D004338:Drug Combinations; D004791:Enzyme Inhibitors; D013629:Tamoxifen; D017258:Medroxyprogesterone Acetate; D000068878:Trastuzumab; D017239:Paclitaxel